EuroPCR 2023 | TAVR in TAVR Results with Balloon-Expandable Valves

With the expansion of transcatheter aortic valve replacement (TAVR) use in the low-risk population, more patients will need repeat valve replacement in the future, making it paramount to understand the performance of repeat TAVR. Currently, this information is limited.

EuroPCR 2023 | ACURATE Neo2: Resultados a 5 años

The aim of this study was to analyze the real-world experience of performing a second TAVR using SAPIEN balloon-expandable valves. A second aim was to compare the safety and efficacy of repeat TAVR compared with initial TAVR, and to determine whether the results are dependent on the transcatheter heart valve (THV) index.

Of 348,338 patients who underwent TAVR with implantation of the EDWARDS balloon-expandable valve between 2011 and 2022, 1216 patients required a second TAVR. Out of these patients, 475 were in the Edwards THV index group and 741 patients were in the non-index THV group. Propensity score matching was used to homogenize the samples.

The primary endpoint (PEP) was death and stroke at 30 days and at 1 year. The secondary endpoint (SEP) was procedural, in-hospital, echocardiographic, and health status outcomes.

Read also: EuroPCR 2023 | Intravascular Lithotripsy (IVL) Balloon in the Treatment of Underexpanded Stents.

Mean patient age was 78 years old, and most subjects were male. The mean Society of Thoracic Surgeons (STS) score was 8.3 for the second TAVR group vs. 5.2 for the initial TAVR group (p < 0.01). In terms of the procedure, transfemoral access was the most common access in both groups, with similar success rates.

Regarding outcomes, there were no differences in the PEP at 30 days and 1 year. In turn, for the SEP, valve reintervention was significantly more frequent in the second TAVR group at 30 days and 1 year.

Conclusion

Performing new TAVR with balloon-expandable valves may be a reasonable therapeutic option for patients with failed initial TAVR. Long-term data are needed to stratify which type of valve is necessary in an initial scenario and which valve in a later scenario.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Outcomes of repeat Transcatheter Aortic Valve Replacement with Ballon-expandable Valves.

Reference: R. Makkar et al.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...